Archives of Women's Mental Health

, Volume 6, Issue 2, pp 147–151

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response

Authors

  • T. Pearlstein
    •  Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • E. Spurell
    •  Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • L. A. Hohlstein
    •  Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • V. Gurney
    •  Laurel Hill Inn Residential Eating Disorder Program, Medford, MA, U.S.A.
  • J. Read
    •  Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • C. Fuchs
    •  Boston, MA, U.S.A.
  • M. B. Keller
    •  Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
Short communication

DOI: 10.1007/s00737-003-0172-8

Cite this article as:
Pearlstein, T., Spurell, E., Hohlstein, L. et al. Arch Womens Ment Health (2003) 6: 147. doi:10.1007/s00737-003-0172-8

Summary

Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

Keywords: Binge eating disorder; fluvoxamine; placebo.
Download to read the full article text

Copyright information

© Springer-Verlag Wien 2003